AtriCureATRC -0.63%76 Operating Margin % is 0.37% as of Mar. 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, AtriCure ranks worse than 56.99% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. AtriCure's Operating Income for the
three
months ended in Mar. 2026 was $0.5 Mil. AtriCure's Revenue for the
three
months ended in Mar. 2026 was $141.2 Mil. Therefore, AtriCure's Operating Margin % for the quarter that ended in Mar. 2026 was 0.37%.
Good Sign:
AtriCure Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for AtriCure's Operating Margin % or its related term are showing as below:
ATRC'
s Operating Margin % Range Over the Past 10 Years
Min: -21.59 Med: -13.61 Max: -0.54
Current: -0.54
ATRC's Operating Margin % is ranked worse than 56.99% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs ATRC: -0.54
AtriCure's 5-Year Average Operating Margin % Growth Rate was 35.30% per year.
AtriCure's Operating Income for the
three
months ended in Mar. 2026 was $0.5 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.0 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
AtriCure Operating Margin % Related Terms
AtriCure Operating Margin % Historical Data
* Premium members only.
The historical data trend for AtriCure's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRC vs STAA, NNNN, KMTS: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, AtriCure's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Operating Margin % distribution charts can be found below:
* The bar in red indicates where AtriCure's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
AtriCure's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (ATRC) has a Operating Margin % of 0.37% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #465 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 57%.
Is AtriCure's Operating Margin % too high?
AtriCure's current Operating Margin % is 0.37%. The Medical Devices & Instruments industry median Operating Margin % is 3.47. AtriCure's value of 0.37% is 89.3% below this industry median. Based on the distribution chart, AtriCure ranks #465 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Operating Margin % compare to STAA and NNNN?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #465 out of 816 companies for Operating Margin %. This places AtriCure in the lower half of its industry. The industry median Operating Margin % is 3.47. AtriCure's value of 0.37% is 89.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current Operating Margin % of 0.37% is 89.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on AtriCure and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current Operating Margin % is 0.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.26 — trading 28.9% below its estimated fair value. The current Operating Margin % is 0.37% and 89.3% below the Medical Devices & Instruments industry median of 3.47. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For AtriCure (ATRC), the current Operating Margin % is 0.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be undervalued.
The current stock price of $28.26 is trading 28.9% below its estimated GF Value™ of $39.73.
GuruFocus considers AtriCure to be Modestly Undervalued.
Key valuation signals for ATRC:
Operating Margin %: 0.37%
GF Value™: $39.73 vs. price of $28.26 (28.9% below fair value)
Industry Position: 89.3% below the Medical Devices & Instruments median (#465 of 816)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score
Get the complete analysis for ATRC
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
